

# Eug ne P Van Puijenbroek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3466157/publications.pdf>

Version: 2024-02-01

109  
papers

3,268  
citations

236612

25  
h-index

168136

53  
g-index

110  
all docs

110  
docs citations

110  
times ranked

2426  
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 3-10.	0.9	822
2	The role of data mining in pharmacovigilance. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 929-948.	1.0	211
3	Use of Measures of Disproportionality in Pharmacovigilance. <i>Drug Safety</i> , 2002, 25, 453-458.	1.4	138
4	On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. <i>Statistics in Medicine</i> , 2002, 21, 2027-2044.	0.8	115
5	Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 689-693.	1.1	108
6	Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 733-738.	0.8	105
7	Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions. <i>Drug Safety</i> , 2003, 26, 293-301.	1.4	104
8	Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1507-1515.	1.1	89
9	Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1143-1150.	0.8	65
10	The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. <i>Drug Safety</i> , 2017, 40, 607-614.	1.4	63
11	Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 579-586.	1.1	54
12	Adverse drug reaction reports of patients and healthcare professionals' differences in reported information. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 152-158.	0.9	54
13	Hyponatraemia as an Adverse Drug Reaction of Antipsychotic Drugs. <i>Drug Safety</i> , 2010, 33, 569-578.	1.4	51
14	Different Risks for NSAID-Induced Anaphylaxis. <i>Annals of Pharmacotherapy</i> , 2002, 36, 24-29.	0.9	50
15	The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 286-291.	0.9	47
16	Influence of Chemical Structure on Hypersensitivity Reactions Induced by Antiepileptic Drugs. <i>Drug Safety</i> , 2008, 31, 695-702.	1.4	42
17	The Impact of Experiencing Adverse Drug Reactions on the Patient's Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands. <i>Drug Safety</i> , 2016, 39, 769-776.	1.4	40
18	Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. <i>Drug Safety</i> , 2020, 43, 489-495.	1.4	34

#	ARTICLE	IF	CITATIONS
19	Photo-onycholysis associated with the use of doxycycline. <i>BMJ: British Medical Journal</i> , 2004, 329, 265.1.	2.4	33
20	Intensive Monitoring of Pregabalin. <i>Drug Safety</i> , 2011, 34, 221-231.	1.4	33
21	Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. <i>Drug Safety</i> , 2020, 43, 339-350.	1.4	30
22	Reporting of Adverse Drug Reactions by General Practitioners. <i>Drug Safety</i> , 2009, 32, 851-858.	1.4	29
23	Longitudinal monitoring of the safety of drugs by using a web-based system: the case of pregabalin. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 591-597.	0.9	29
24	Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device. <i>Drug Safety</i> , 2011, 34, 83-88.	1.4	28
25	Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 26-32.	0.9	27
26	Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or Hyponatraemia Associated with Valproic Acid. <i>Drug Safety</i> , 2010, 33, 47-55.	1.4	27
27	Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. <i>Drug Safety</i> , 2018, 41, 859-869.	1.4	27
28	Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. <i>Drug Safety</i> , 2010, 33, 1097-1108.	1.4	26
29	A global view of undergraduate education in pharmacovigilance. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 891-899.	0.8	26
30	Effectiveness of Pharmacovigilance Training of General Practitioners. <i>Drug Safety</i> , 2011, 34, 755-762.	1.4	25
31	Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 209-215.	0.8	24
32	Important information regarding reporting of adverse drug reactions: a qualitative study. <i>International Journal of Pharmacy Practice</i> , 2014, 22, 231-233.	0.3	23
33	Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. <i>Drug Safety</i> , 2017, 40, 409-418.	1.4	22
34	Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. <i>Drug Safety</i> , 2018, 41, 677-683.	1.4	22
35	Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 135-142.	0.9	20
36	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	1.4	20

#	ARTICLE	IF	CITATIONS
37	Data mining in pharmacovigilance: lessons from phantom ships. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 967-970.	0.8	19
38	Drug-Related Nephrotoxic and Ototoxic Reactions. <i>Drug Safety</i> , 2008, 31, 877-884.	1.4	19
39	Pharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors – A Nationwide Study in the Netherlands. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 475-481.	1.2	19
40	A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 199-205.	0.9	19
41	Time course, outcome and management of adverse drug reactions associated with metformin from patient's perspective: a prospective, observational cohort study in the Netherlands. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 615-622.	0.8	18
42	Web-based questionnaires to assess perinatal outcome proved to be valid. <i>Journal of Clinical Epidemiology</i> , 2017, 90, 136-143.	2.4	18
43	Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana. <i>Drug Safety</i> , 2017, 40, 911-921.	1.4	18
44	Do pharmacists' reports of adverse drug reactions reflect patients' concerns?. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 155-159.	1.4	17
45	Expectations for Feedback in Adverse Drug Reporting by Healthcare Professionals in the Netherlands. <i>Drug Safety</i> , 2011, 35, 1.	1.4	17
46	When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 296-303.	2.3	17
47	Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. <i>Thyroid</i> , 2020, 30, 821-828.	2.4	17
48	The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles. <i>International Journal of Clinical Pharmacy</i> , 2003, 25, 260-263.	1.4	16
49	Clindamycin and taste disorders. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 542-545.	1.1	16
50	The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 17-26.	1.4	16
51	Spontaneous ADR Reports as a Trigger for Pharmacogenetic Research. <i>Drug Safety</i> , 2009, 32, 255-264.	1.4	15
52	Fever Following Immunization with Influenza A (H1N1) Vaccine in Children. <i>Drug Safety</i> , 2010, 33, 1109-1115.	1.4	15
53	Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1514-1524.	1.1	15
54	Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 870-871.	1.1	14

#	ARTICLE	IF	CITATIONS
55	The value of timeâ€œonset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1361-1367.	0.9	14
56	The validity and reliability of a signal impact assessment tool. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 815-819.	0.9	11
57	The International Pharmacy Game: A Comparison of Implementation in Seven Universities World-Wide. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 125.	0.6	11
58	Myopathy Due to Statin/Fibrate Use in the Netherlands. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1957-1960.	0.9	10
59	Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone. <i>BMJ: British Medical Journal</i> , 2004, 328, 1353.	2.4	10
60	Experiences with the Use of Varenicline in Daily Practice in the Netherlands: A Prospective, Observational Cohort Study. <i>Drug Safety</i> , 2014, 37, 449-457.	1.4	10
61	Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: Description of a prospective cohort and spontaneously reported pregnancyâ€œrelated adverse reactions in the Netherlands. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 731-738.	1.6	10
62	Numbers of spontaneous reports: how to use and interpret?. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	10
63	Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e228224.	2.8	10
64	Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 99-105.	0.9	9
65	Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1461-1462.	0.8	9
66	Feedback for patients reporting adverse drug reactions; satisfaction and expectations. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 625-632.	1.0	9
67	Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 382-410.	2.5	9
68	Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1617-1624.	1.0	9
69	Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africaâ€œEthiopia, Kenya, Rwanda, and Tanzania. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1941.	1.2	9
70	Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. <i>Drug Safety</i> , 2022, 45, 145-153.	1.4	9
71	Post Launch Monitoring of food products: What can be learned from pharmacovigilance. <i>Regulatory Toxicology and Pharmacology</i> , 2007, 47, 213-220.	1.3	8
72	Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 76-81.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Representativeness of diabetes patients participating in a web-based adverse drug reaction monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 250-255.	0.9	8
74	Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1175-1179.	0.9	8
75	Relationship Between Structural Alerts in NSAIDs and Idiosyncratic Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database. <i>Drug Safety</i> , 2015, 38, 511-515.	1.4	7
76	Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054.	1.0	6
77	Hearing Impairment Associated with Oral Terbinafine Use. <i>Drug Safety</i> , 2012, 35, 685-691.	1.4	5
78	Discontinuation of metformin to prevent metformin-induced high colonic FDG uptake: is 48h sufficient?. <i>Annals of Nuclear Medicine</i> , 2020, 34, 833-839.	1.2	5
79	Hearing Impairment Associated with Oral Terbinafine Use. <i>Drug Safety</i> , 2012, 35, 685-691.	1.4	5
80	Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 699-706.	1.0	5
81	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 597-599.	0.5	5
82	Mirtazapine-induced arthralgia. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 570-572.	1.1	4
83	Monitoring adverse events of vaccines against Mexican flu. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 81-87.	0.3	4
84	Assessment of medication use during pregnancy by Web-based questionnaires, pharmacy records and serum screening. <i>Reproductive Toxicology</i> , 2019, 84, 93-97.	1.3	4
85	Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana. <i>Ghana Medical Journal</i> , 2019, 53, 150.	0.1	4
86	Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1283-1289.	0.9	4
87	Male Sexual Health and Reproduction in Cutaneous Immune-Mediated Diseases: A Systematic Review. <i>Sexual Medicine Reviews</i> , 2020, 9, 423-433.	1.5	4
88	Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. <i>Drug Safety</i> , 2021, 44, 211-222.	1.4	4
89	Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. <i>Frontiers in Medical Technology</i> , 2021, 3, 629750.	1.3	4
90	Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach. <i>PLoS ONE</i> , 2022, 17, e0264699.	1.1	4

#	ARTICLE	IF	CITATIONS
91	Spontaneous Reports and Pharmacogenetics. <i>Drug Safety</i> , 2009, 32, 357-358.	1.4	3
92	Parametric time-to-onset models were developed to improve causality assessment of adverse drug reactions from antidiabetic drugs. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1423-1431.	2.4	3
93	Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands. <i>International Journal of Risk and Safety in Medicine</i> , 2016, 28, 115-123.	0.3	3
94	Contraindicated use of 5 $\alpha$ -reductase inhibitors in women. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 429-431.	1.1	3
95	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 923-935.	0.9	3
96	Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review. <i>Vaccines</i> , 2021, 9, 111.	2.1	3
97	Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 417-423.	1.0	3
98	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. <i>Drug Safety</i> , 2019, 42, 683-687.	1.4	2
99	Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1521-1528.	1.0	2
100	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	1.0	2
101	Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 27.	1.8	2
102	Broadening the Scope of Pharmacovigilance. , 2017, , 131-144.		1
103	Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 869-874.	1.0	1
104	Anaphylactic Reaction to Tc-99m Macrosalb. <i>Drug Safety - Case Reports</i> , 2019, 6, 4.	0.9	1
105	Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. <i>Drug Safety</i> , 2020, 43, 319-328.	1.4	1
106	Retroperitoneal fibrosis and $\beta$ -blocking agents: Is there an association?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2891-2901.	1.1	1
107	Electronic Health Record-Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. <i>JMIR Medical Informatics</i> , 2022, 10, e33250.	1.3	1
108	Response to the validity and reliability of a signal impact assessment tool: statistical issue to avoid misinterpretation. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1217-1217.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Patients'™ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	0